| Literature DB >> 30254215 |
Małgorzata Rydzanicz1, Małgorzata Wachowska2, Erik C Cook3, Paweł Lisowski4,5, Bożena Kuźniewska6, Krystyna Szymańska7, Sebastian Diecke5, Alessandro Prigione5, Krzysztof Szczałuba1, Aleksandra Szybińska8, Agnieszka Koppolu1,9, Victor Murcia Pienkowski1,9, Joanna Kosińska1, Małgorzata Wiweger8, Grażyna Kostrzewa1, Małgorzata Brzozowska10, Dorota Domańska-Pakieła11, Elżbieta Jurkiewicz12, Piotr Stawiński1, Agnieszka Gromadka13, Piotr Zielenkiewicz13, Urszula Demkow2, Magdalena Dziembowska6, Jacek Kuźnicki8, Trevor P Creamer3, Rafał Płoski14.
Abstract
PPP3CA encodes calmodulin-binding catalytic subunit of calcineurin, a ubiquitously expressed calcium/calmodulin-regulated protein phosphatase. Recently de novo PPP3CA variants were reported as a cause of disease in 12 subjects presenting with epileptic encephalopathy and dysmorphic features. We describe a boy with similar phenotype and severe early onset epileptic encephalopathy in whom a novel de novo c.1324C>T (p.(Gln442Ter)) PPP3CA variant was found by whole exome sequencing. Western blot experiments in patient's cells (EBV transformed lymphocytes and neuronal cells derived through reprogramming) indicate that despite normal mRNA abundance the protein expression level is strongly reduced both for the mutated and wild-type protein. By in vitro studies with recombinant protein expressed in E. coli we show that c.1324C>T (p.(Gln442Ter)) results in constitutive activation of the enzyme. Our results confirm the role of PPP3CA defects in pathogenesis of a distinct neurodevelopmental disorder including severe epilepsy and dysmorphism and provide further functional clues regarding the pathogenic mechanism.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30254215 PMCID: PMC6303256 DOI: 10.1038/s41431-018-0254-8
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246